Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
|
|
- Dorothy Osborne
- 6 years ago
- Views:
Transcription
1 BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Alan Winston: Statement Dr. Winston has been awarded investigator initiated study grants, received speaker honorarium or attended advisory boards for Abbott, Boehringer-Ingelheim, BMS, Gilead Sciences, GSK, Merk & Co., Pfizer, Tibotec and ViiV Healthcare. Date 27 September October 2010, Queen Elizabeth II Conference Centre, London 1
2 The CNS penetration effectiveness score: What does it mean? Alan Winston St. Mary s Hospital, London October 2010 UK CHIC any CNS event PML TOXO CRYP HIVe /7 1998/9 2000/1 2002/3 2004/5 2006/7 Garvey et al PS6/5 Cologne EACS November
3 HIV associated dementia in cart era Dore: AIDS, Volume 17(10).July 4, St. Mary s Cohort % anci Interquartile age groups (years) 45 subjects on ART with plasma HIV RNA<50 copies/ml anciobserved in14/45 (31%) subjects associated with younger age (p=0.03) AIDS Res Hum Retroviruses Aug;25(8):
4 Why do we need a CNS penetration score? CNS penetration of ART Scoring instruments The evidence 4
5 CNS penetration of ART Scoring instruments The evidence CNS drug penetration Solon E, et al. Drug Metab Dispos. 2002;30:
6 CSF : plasma ratios Antiretroviral Agent CSF : plasma ratio Commentson study Reference NRTIs abacavir 36 % AntimicrobAgents Chemother49, (2005) didanosine N.D. PharmWorld Sci17, (1995) emtricitabine 43 % 16th CRIO Montreal, Canada: poster 702 lamivudine 30 % Lancet 351, (1998) tenofovir 4 % unlikelytoexceedwildtypeic 50fortenofovir 15th CROI. 2008: Boston, MA zidovune 40 % Lancet 351, (1998) NNRTIs efavirenz 0.5 % below1%-maybesufficienttosuppresswildtypevirus 16th CROI Montreal, Canada: poster 702. nevirapine 63 % thehighestcsf:plasmaratiodescribedtodate Clin Infect Dis 41, (2005) Boosted PIs atazanavir < 1 % unlikelytobeabovetheic 50forwildtypevirus AIDS 23, 83-7 (2009) lopinavir 0.23 % AIDS 19, (2005) darunavir 0.8 % intherangerequiredtosuppressionwildtypevirus AIDS Res Hum Retroviruses 25, (2009) Other classes maraviroc 2% J AcquirImmune DeficSyndr Aug 11 raltegravir 3% PLoSOne Sep 1;4(9) N.D. not detected in CSF in studies to date CNS penetration reference score Abacavir CSF concentrations Abacavir Concentration (ng/ml) Plasma CSF Time After Dose (hours) Limitations Definition of IC 50 Inter-subject variability CSF exposure, not cerebral Population studied IC 50 =70 ng/ml CapparelliEV et al. AntimicrobAgents Chemother. 2005;49:
7 Raltegravir and CSF IC 95 PLoS One Sep 1;4(9) Raltegravir and CSF PLoS One Sep 1;4(9) 7
8 A new approach to classification Highest Level of evidence Lowest Pharmacodynamics Pharmacokinetics Drug characteristics Clinical results Incidence of NCI NC function Concentration above IC 50 Definition of IC 50 Consistent with CNS penetration CNS Penetration effectiveness score (CPE): 2007 additive score 0 / 0.5 / additive score 1 / 2 / 3 / 4 LetendreS et al. ArchNeurol2008;65:65-70 / LetendreS et al. CROI 2010, Poster 430 CNS penetration of ART Scoring instruments The evidence 8
9 The evidence in HIV infection Management of OIs Management of HIV infection Survival PML and CNS penetrating cart Gasnault et al. CROI 2008 abstract 385 9
10 The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects o Neurosymptomatic subjects The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects Primary HIV infection 10
11 Primary HIV infection Animal model: 8 rhesus monkeys infected SIV 4 (50%) Rx ART (tenofovir plus nelfinavir) 4 (50%) Rx placebo All CNS parameters normalised in active Rx group Locomotor activity AIDS 2009, 23: The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects Primary HIV infection Electively commencing ART 11
12 Electively commencing ART Odds Ratios for Cognitive Impairment According to CD4 Nadir Strata (All Subjects) Neurology sub-study START Ellis et al. CROI 2010, poster 429 Electively commencing ART ALTAIR study ART-naïve study, examining 3 randomised treatment arms: 1.TDF/FTC + EFV 2.TDF/FTC + ATV/r 3.TDF/FTC + AZT + ABC CNS sub-study Neurocognitive function computerised testing at baseline and week 48 Cerebral 1 H-MRS at baseline and week 48 Subject characteristics Overall N=30, EFV (N=9), ATV/r (N=9) and AZT/ABC (N=12) All neuro-asymptomatic Winston A, Duncombe C, et al. Clin Infect Dis Mar 15;50(6):
13 ALTAIR NC testing results: Composite speed score Executive function Composite speed change (baseline to week 48) Change number of errors ( baseline to week 48) p=0.15 p=0.04 p=0.71 p= TDF/FTC/EFV TDF/FTC/ATV/r TDF/FTC/AZT/ABC TDF/FTC/EFV TDF/FTC/ATV/r TDF/FTC/AZT/ABC Changes in cerebral metabolites NAA Cho Cr p=0.041 p= mi TDF/FTC/EFV TDF/FTC/ATV/r TDF/FTC/AZT/ABC Summary: Greater improvements in NC function testing observed in the quadruple NRTI arm Greater recovery in neuronal CNS metabolites were observed in the EFV-containing arm Data suggest that different ART may have different cerebral effects Winston A, Duncombe C, et al. Clin Infect Dis Mar 15;50(6):920-9 Neuronal damage and ART Frontal White Matter NAA Total months exposure NRTIs Journal of NeuroVirology, 11: ,
14 Neuronal damage and ART Neurons stained for microtubule-associated protein-2 (MAP-2): (A) normal untreated cultures (B) dendritic beading (C) pruning of dendrites (D) loss of neuron density Following 6 days exposure to ARVs at reported plasma concentrations: (B) and (C) cultures treated with atazanavir (D) maximal damage seen with efavirenz CROI 2010, poster 435 The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects Primary HIV infection Electively commencing ART Stable on ART 14
15 Subjects on ART To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition, n=101 Higher CPE scores correlate with: lower CSF viraemia lower NC performance CSF HIV RNA NC performance Variable Odds-ratio LCL UCL P Value Variable Odds-ratio LCL UCL P Value Nadir CD4 count NNRTI Regimen Number of ARV Agents CPE rank Entry NPZ <0.001 CSF HIV RNA < Number of ARV Agents CPE rank <0.001 ARV includes efavirenz Marra et al. AIDS Jul 17;23(11): CPE score in the UK (CHIC) Factors independently associated with a CPE score >3 included greater pre-treatment HIV RNA level (p=0.005) calendar year (2000 and 2003, p<0.0001) female heterosexual subjects were less likely to be prescribed cart with a CPE score >3 than individuals from other HIV risk groups (p<0.0001). Garvey, Winston, Sabin. CROI 2010 poster
16 The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects Primary HIV infection Electively commencing ART Stable on ART Novel treatment approaches PI monotherapy 1 MONET: Changes in FAHI Cognitive Functioning Score over 48 weeks between study treatment arms DRV/r 2 MOST: Study terminated DRV/r + NRTIs 3 PIVOT: Study week 1. HIV Clin Trials May-Jun;11(3):163-9 / 2. AIDS Sep 24;24(15):
17 The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects o Neurosymptomatic subjects Not on ART On ART Detectable plasma viraemia Undetectable plasma viraemia Abacavir dementia study Study design Neurocognitively impaired HIV-infected subjects on ART eligible Randomised to ABC or placebo Primary outcome change NPZ-score N=105 Lack efficacy inefficacy of ABC per se prolonged benefit from existing therapy differences baseline characteristics baseline drug resistance CSF and plasma HIV-1 RT genotypes were discordant in 14/21 (67%) After 12 weeks ABC + SBT SBT Number subjects Change NPZ-score Rangechange in score to to 3.32 Balanced CPE score PLoS Clin Trials Mar 30;2(3): 17
18 Balanced CPE score Genetic distance between CSF and plasma virus: 39 subjects on ART with HIV encephalopathy high genetic distance associated with o undetectable plasma viral load o low-balanced CPE score The detectable viral loads in plasma might favour virus diffusion across the blood brain barrier and high-balanced CPE score could prevent the viral replication in the CNS compartment AIDS 2010, 24: The evidence in HIV infection Management of OIs Management of HIV infection o Neuroasymptomatic subjects o Neurosymptomatic subjects Not on ART On ART Detectable plasma viraemia Undetectable plasma viraemia 18
19 CNS penetration effectiveness score: What does it mean? Advancement in scoring system assessing CNS drug penetration o Not just using CSF:plasma ratios Limitations o o o o o o Scores most often based on PK not PD data (PK data have limitations) Cerebral toxicities of ART not considered and may be paramount Clinical scenarios where CNS penetration may be important remain unknown Cohort studies may report biased results as CPE score biased Encompassing measures of drug resistance challenging Drug-drug interactions The evidence in HIV infection Management of Ois Management of HIV infection o Neuroasymptomatic subjects Primary HIV infection Electively commencing ART Stable on ART Novel treatment approaches o Neurosymptomatic subjects Not on ART On ART Detectable plasma viraemia Undetectable plasma viraemia 19
20 CNS Penetration Effectiveness Score (CPE) NRTIs Abacavir Zidovudine Emtricitabine Lamivudine Stavudine NNRTIs Nevirapine Efavirenz PIs Fusion inhibitors Amprenavir Indinavir Lopinavir Atazanavir Didanosine Tenofovir Nelfinavir Ritonavir Saquinavir Tipranavir Enfuvirtide Letendre S et al. Arch Neurol 2008;65:65-70 CNS Penetration Effectiveness Score (CPE) NRTIs Zidovudine Abacavir Emtricitabine NNRTIs Nevirapine Delavirdine Efavirenz Didanosine Lamivudine Stavudine Etravirine Tenofovir Zalcitabine PIs Indinavir-r Darunavir-r Fosamprenavir-r Indinavir Lopinavir-r Entry/Fusion Inhibitors Maraviroc Atazanavir Atazanavir-r Fosamprenavir Nelfinavir Ritonavir Saquinavir Saquinavir-r Tipranavir-r Enfuvirtide Integrase Inhibitors Raltegravir Letendre S et al. CROI 2010, Poster
HIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Associated Neurocognitive Disorders in the era of modern CART
HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationAntiretroviral drug treatment of CNS HIV-1 infection
J Antimicrob Chemother 2012; 67: 299 311 doi:10.1093/jac/dkr492 Advance Access publication 8 December 2011 Antiretroviral drug treatment of CNS HIV-1 infection Aylin Yilmaz 1 *, Richard W. Price 2 and
More informationART rapid scale up: the implications for patient care and retention. Dr Francesca Conradie Southern African HIV Clinicians Society
ART rapid scale up: the implications for patient care and retention Dr Francesca Conradie Southern African HIV Clinicians Society Agenda Why do we need rapid scale up? Is there enough evidence for rapid
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationNuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells
Under The Microscope: The Impact of ARTs Nuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells Gary N.Y. Chan, Ph. D. Candidate Supervisor:
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationHigh rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents YasotharanParamesparan, Jane Ashby, Lucy Garvey, Caroline Foster, Sarah Fidler, Alan Winston Background
More informationOptimizing ARV For Women
Optimizing ARV For Women Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University
More informationAntiviral Therapy 2015; 20: (doi: /IMP2926)
Antiviral Therapy 2015; 20:441 447 (doi: 10.3851/IMP2926) Original article Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationStatistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University
Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationU=U NHIVNA HIV, Fertility and Contraception in the era of
HIV, Fertility and Contraception in the era of U=U NHIVNA 2018 Yvonne Gilleece Consultant in HIV and Sexual Health Brighton &Sussex University Hospitals NHS Trust Honorary Senior Lecturer Brighton & Sussex
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationClinical notes: Management of HAART in patients with HAND
Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology
More informationAntiviral Therapy 2013; 18: (doi: /IMP2560)
Antiviral Therapy 2013; 18:153 160 (doi: 10.3851/IMP2560) Original article Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationDr Lucy Garvey. Imperial College Healthcare NHS Trust, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Lucy Garvey Imperial College Healthcare NHS Trust, London 18-20 April 2012, The International Convention Centre, Birmingham Microglial
More information